Sunday, July 5, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

A Legendary Short Seller Takes Aim at Palantir’s Core

Jackson Burston by Jackson Burston
February 16, 2026
in AI & Quantum Computing, Analysis, Cyber Security, Defense & Aerospace, Tech & Software
0
Palantir Stock
0
SHARES
19
VIEWS
Share on FacebookShare on Twitter

The data analytics firm Palantir finds itself in the crosshairs of a prominent critic. Michael Burry, the investor famed for predicting the 2008 financial crisis, has significantly escalated his public campaign against the company. His latest move shifts the battleground from technical chart analysis to questions of corporate ethics, creating a stark contrast with Palantir’s recent stream of high-profile contract wins.

From Chart Patterns to Allegations

Burry’s critique entered a new phase over the weekend. Moving beyond financial metrics, he took to social media to demand evidence for what he characterized as the company’s alleged covert smear campaigns. His statements employed sarcastic references to underscore a deep-seated skepticism regarding Palantir’s governance.

This ethical offensive follows a purely technical warning issued just days prior. On February 10, Burry identified a bearish “head and shoulders” pattern in Palantir’s stock chart, suggesting a potential downward price target around $60. Given the share price of approximately $131.41 at the time, such a move would represent a severe correction. The combination of a technical sell signal and qualitative attacks marks a clear intensification in his stance against the stock.

Operational Momentum Provides a Counter-Narrative

Fundamentally, the short seller’s pessimism is challenged by a robust operational backdrop. On February 12, the US Defense Information Systems Agency (DISA) granted Palantir an expanded authorization. This clearance allows for the deployment of its software directly at the “Tactical Edge,” deepening the company’s embedded role within the defense sector.

Should investors sell immediately? Or is it worth buying Palantir?

Almost concurrently, on February 10, the aerospace giant Airbus confirmed an extension of its long-term partnership with Palantir for the Skywise data platform. These developments bolster the argument made by bullish investors that institutional demand for AI-driven solutions is accelerating, irrespective of stock price volatility.

Valuation Tensions Under a Spotlight

This conflict plays out against a backdrop of already stretched valuations. Following a 70% surge in revenue reported for the fourth quarter, the stock trades at historically elevated levels. Market participants are now weighing the warning from a legendary investor against the tangible evidence of commercial and governmental expansion.

The central question for the week ahead is whether Burry’s vocal criticism will be powerful enough to disrupt the positive momentum generated by the recent Airbus and US military contracts. The outcome will hinge on which narrative the market chooses to prioritize: the ethical and technical concerns of a famed contrarian, or the demonstrable growth in Palantir’s core business.

Ad

Palantir Stock: Buy or Sell?! New Palantir Analysis from July 5 delivers the answer:

The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 5.

Palantir: Buy or sell? Read more here...

Tags: Palantir
Jackson Burston

Jackson Burston

Related Posts

Bayer Stock
Analysis

Bayer’s Rally Faces a New Test: Antidumping Bid vs. Overbought Charts After Court Win

July 4, 2026
Outlook Therapeutics Stock
Analysis

Outlook Therapeutics Braces for a Five-Day Gauntlet: Shareholder Vote on Survival Followed by FDA Decision on ONS-5010

July 4, 2026
Mercedes-Benz Stock
Analysis

Mercedes-Benz Stock Mounts Comeback as Labor Dispute Escalates Over Soured Bonus Payments

July 4, 2026
Next Post
Ge Vernova Stock

Institutional Investors Amplify Stakes in GE Vernova Amid Lofty Valuation

Netflix Stock

Bidding War Intensifies Over Warner Bros Discovery as Paramount Ups Ante

22nd Century Stock

Can 22nd Century Group Achieve Profitability by Its 2026 Target?

Recommended

BioNTech Stock

Institutional Investors Double Down on BioNTech’s Strategic Pivot

4 months ago
Driven Brands Holdings Stock

Diverging Signals: Insider Selling Meets Analyst Confidence at Driven Brands

10 months ago
Polestar Auto.adr/a Stock

Polestar’s Financial Crisis Deepens Amidst Surging Sales

9 months ago
Gold Stock

Gold’s Year-End Rally Evaporates as Rate Cut Hopes Fade

8 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Digital Forklift Checklists and a Growing Cyber Threat: Inside Germany’s New Electrical Safety Rules

Outlook Therapeutics Braces for a Five-Day Gauntlet: Shareholder Vote on Survival Followed by FDA Decision on ONS-5010

Starbase Static Fire Clears Path for Next Starship Test as SpaceX Stock Hovers at a Crossroads

Mercedes-Benz Stock Mounts Comeback as Labor Dispute Escalates Over Soured Bonus Payments

Intuit’s Valuation Discount Is Tempting — But Lawsuits and a DIY Price War Keep Buyers at Bay

Realbotix Faces a Pivotal Gamble: Nasdaq Listing Hinges on Supply Chain and Shareholder Approval

Trending

Bayer Stock
Analysis

Bayer’s Rally Faces a New Test: Antidumping Bid vs. Overbought Charts After Court Win

by Rodolfo Hanigan
July 4, 2026
0

Just five days after a landmark Supreme Court victory, Bayer has opened a second front in its...

Antimony Resources Stock

Antimony Resources: A Geopolitical Bet Gets a Geological Boost

July 4, 2026
ITM Power Stock

ITM Power: Inside the 113% Volatility Stock That Just Attracted a Government Stake and a Rheinmetall Pact

July 4, 2026
FALLBACK Stock

Digital Forklift Checklists and a Growing Cyber Threat: Inside Germany’s New Electrical Safety Rules

July 4, 2026
Outlook Therapeutics Stock

Outlook Therapeutics Braces for a Five-Day Gauntlet: Shareholder Vote on Survival Followed by FDA Decision on ONS-5010

July 4, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Bayer’s Rally Faces a New Test: Antidumping Bid vs. Overbought Charts After Court Win
  • Antimony Resources: A Geopolitical Bet Gets a Geological Boost
  • ITM Power: Inside the 113% Volatility Stock That Just Attracted a Government Stake and a Rheinmetall Pact

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com